1-3 of 3
Jocelyn Holash
Close
Sort by
Journal Articles

The Pan-PIM Kinase Inhibitor LGH447 Shows Activity In PIM2-Dependent Multiple Myeloma and In AML Models

Pablo D Garcia, PhD, John L Langowski, Ph.D., Jocelyn Holash, Ph.D., Matthew Burger, Ph.D., Richard Zang, Ph.D., Tatiana Zavorotinskaya, PhD, Christie Fanton, PhD, Abdel Saci, Ph.D., Joseph Growney, Ph.D., K. Gary Vanasse, M.D.
Journal: Blood
Blood (2013) 122 (21): 1666.
https://doi.org/10.1182/blood.V122.21.1666.1666
Published: 2013
Journal Articles

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

Jing Lu, Tatiana Zavorotinskaya, Yumin Dai, Xiao-Hong Niu, Joseph Castillo, Janet Sim, Jianjun Yu, Yingyun Wang, John L. Langowski, Jocelyn Holash, Kevin Shannon, Pablo D. Garcia
Journal: Blood
Blood (2013) 122 (9): 1610–1620.
https://doi.org/10.1182/blood-2013-01-481457
Published: 2013
Includes: Supplemental data
Journal Articles

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios V. Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, III, Sang Hoon Lee, Sharon Lea Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William Wierda, Susan O'Brien, Anas Younes
Journal: Blood
Blood (2008) 112 (3): 711–720.
https://doi.org/10.1182/blood-2007-04-084756
Published: 2008